Kazia Therapeutics (KZIA) Shares Outstanding (Weighted Average) (2009 - 2025)
Kazia Therapeutics (KZIA) posted Shares Outstanding (Weighted Average) of $122.5 million for Q4 2025, up 55.47% on a QoQ basis from $78.8 million in Q2 2025, and up 761851510.41% year-over-year from N/an in Q4 2024.
Kazia Therapeutics (KZIA) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $122.5 million in Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) rose 761851510.41% year-over-year to $122.5 million; the TTM figure through Dec 2025 stood at $122.5 million (up 761851510.41% YoY), while the FY2025 annual figure was $78.8 million, up 17.65% from the prior year.
- Shares Outstanding (Weighted Average) rose to $122.5 million in Q4 2025, from $78.8 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $122.5 million in Q4 2025 and bottomed at $16.08 in Q4 2024.
- A 5-year average of $66.0 million and a median of $67.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) tumbled 100.0% — and 2025, when it jumped 761851510.41%.
- Year by year, Shares Outstanding (Weighted Average) stood at $101.7 million in 2021, then sank by 41.61% to $59.4 million in 2022, then tumbled by 100.0% to $2395.6 in 2023, then plunged by 99.33% to $16.08 in 2024, then jumped by 761851510.41% to $122.5 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $122.5 million (Q4 2025), $78.8 million (Q2 2025), and $16.08 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Kazia Therapeutics | 1.55 Bn | 1.55 Bn | - | 122.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 122.51 Mn |
| Jun 30, 2025 | 78.80 Mn |
| Dec 31, 2024 | 16.08 |
| Jun 30, 2024 | 219.36 Mn |
| Dec 31, 2023 | 2,395.64 |
| Jun 30, 2023 | 65.13 Mn |
| Dec 31, 2022 | 59.36 Mn |
| Jun 30, 2022 | 99.39 Mn |
| Jun 30, 2021 | 101.66 Mn |
| Dec 31, 2020 | 52.91 Mn |
| Jun 30, 2020 | 62.00 Mn |
| Dec 31, 2019 | 44.74 Mn |
| Jun 30, 2019 | 43.55 Mn |
| Dec 31, 2018 | 26.29 Mn |
| Jun 30, 2018 | 36.65 Mn |
| Dec 31, 2017 | 675.98 |
| Jun 30, 2017 | 363.05 Mn |
| Dec 31, 2016 | -121.69 Mn |
| Jun 30, 2016 | 319.16 Mn |
| Jun 30, 2012 | 1,313.69 |
| Dec 31, 2011 | 134.57 Mn |
| Jun 30, 2011 | 206.28 Mn |
| Dec 31, 2010 | 131.45 Mn |
| Jun 30, 2010 | 182.48 Mn |
| Dec 31, 2009 | 120.98 Mn |
| Jun 30, 2009 | 156.66 Mn |